AR and prostate carcinoma: PARP1 activity is significantly increased in CRPC cells compared to that in hormone-sensitive prostate cancer cells, and PARP inhibitors cause the depletion of both the androgen receptor (AR) and PARP1 on DNA in CRPC cells in vitro and in vivo [53].